Key result
New oral anticoagulants are non-inferior to warfarin in the prevention and treatment of thromboembolic events, offering advantages such as fixed dosing and no need for routine monitoring.
Why the study?
Do new oral anticoagulants prevent thromboembolic events as effectively and safely as warfarin in patients requiring anticoagulation?
Do new oral anticoagulants prevent thromboembolic events as effectively and safely as warfarin in patients requiring anticoagulation?
New oral anticoagulants offer a safe, effective, and convenient alternative to warfarin for thromboembolism prevention, particularly in non-valvular atrial fibrillation, with a notable reduction in intracranial hemorrhage.
Answers are grounded in this paper and cite their sources.
Supports NOAC preference for convenience in eligible patients; leaves open need for targeted RCTs in underrepresented groups.
Oral anticoagulants are medications that have an important place in the prevention and treatment of thromboembolic events that can be seen in the course of many diseases today. Warfarin, vitamin K antagonists are the most commonly known and used oral anticoagulants. Drugs known as new oral anticoagulants have emerged due to the difficulties in treatment and follow-up with warfarin. New oral anticoagulants exhibit anticoagulant effects, disrupting the structure and function of some factors in the coagulation cascade. There are many advantages such as monitorisation requirement, constant dose use, patient compliance and ease of follow-up. Meta-analyzes of large studies with new oral anticoagulants have shown that they are non-inferior from warfarin in the prevention and treatment of thromboembolic events, and even superior in some cases. Due to the ease of use and advantages of these new agents, they have been rapidly spreading and taking place in the prevention and treatment of embolism and ischemic events. Therefore, the areas of use of these drugs, the location of treatment, follow-up, possible side effects and most importantly management of bleeding complications should be well known and applied.
No takes yet. Share an insight, caveat, or question.
Hüseyin Kandemir (2018) conducted a review in Thromboembolic events. New oral anticoagulants vs. Warfarin was evaluated. New oral anticoagulants are non-inferior to warfarin in the prevention and treatment of thromboembolic events, offering advantages such as fixed dosing and no need for routine monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: